GlaxoSmithKline News and Research

RSS

Rosiglitazone therapy associated with increased risk for heart attack: Study

Eleven years after the introduction of the diabetes drug rosiglitazone, data from available clinical trials demonstrate an increased risk for heart attack associated with its use and suggest an unfavorable benefit-to-risk ratio, according to a report posted online today that will appear in the July 26 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Jun 2010

Research provides hope and encouragement to people living with lupus

Research presented during the 9th International Lupus Congress held in Vancouver, Canada from June 24-27, 2010 should give hope and encouragement for the future of the treatment and management of lupus to the 1.5 million Americans and 5 million people worldwide living with lupus. In recent years, there have been significant advances made in many areas of lupus research including the development of new treatments, adult stem cell transplantation, genetics, lupus-related cardiovascular disease, and quality of life issues for people with lupus.

25 Jun 2010

Report identifies FDA's weaknesses in monitoring foreign drug trials

The FDA inspected 0.7 percent of foreign clinical drug trial sites in 2008 while 80 percent of applications approved for marketing that year contained data from foreign drug trials, according to a report (.pdf) from the Inspector General of HHS, CBS News reports (Strickler, 6/22).

24 Jun 2010

BioWa signs two licensing agreements with GSK

BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.

23 Jun 2010

Misperceptions about 'light,' 'low,' 'mild' cigarettes

Today, new legislation will go into effect surrounding the ban of word descriptors such as "light," "low," and "mild" on all packaging and advertising of existing cigarettes and smokeless products. However, a new survey, sponsored by GlaxoSmithKline (GSK) Consumer Healthcare, shows that many smokers will choose the cigarettes in lighter-colored packaging because they incorrectly believe these cigarettes would be less harmful to their health or make it easier to quit smoking.

23 Jun 2010

GSK, Medivir sign exclusive agreement for commercialization of Xerclear

GlaxoSmithKline and Medivir today announced an exclusive agreement for the commercialization of cold sore treatment, Xerclear (acyclovir and hydrocortisone) for non-prescription use (OTC) in key global markets. Xerclear is the first and only topical herpes labialis (cold sores) treatment clinically proven to help prevent cold sore lesions appearing.

23 Jun 2010

European drugmakers lead in making medicines available to developing world, Index says

European drug companies came out ahead of their U.S. counterparts in making medicines available to people in developing countries, but their lead is beginning to shrink, according to the Access to Medicines Index, released on Monday, Reuters reports (Kelland, 6/21).

23 Jun 2010

Opinions: Canada's role in global health; Drug licensing agreements promote drug access; Funding for USAID, state; Haiti

After outlining the work of the Global Fund to Fight AIDS, Tuberculosis and Malaria, Michel Kazatchkine, the organization's executive director, highlights the role Canada can play in determining "whether the world can overcome AIDS, tuberculosis and malaria" in a Toronto Star opinion piece, noting the upcoming G8 and G20 summits, as well as the Millennium Development Goal meeting later this year.

23 Jun 2010

EIN News expands health news-monitoring coverage

With impending lawsuits from states, an uprising from the Tea Party sect and an outpouring of rhetoric from both major parties, the healthcare debate is far from over.

21 Jun 2010

GSK acquires exclusive marketing rights for new topical patch from Labtec GmbH

In a recently finalized license agreement, the Consumer Healthcare division of GlaxoSmithKline acquired the exclusive marketing rights for a new topical patch for the treatment of cold sores from Labtec GmbH, the transdermal and topical patch specialist based in Langenfeld, Germany. The agreement designates Labtec as the exclusive manufacturer.

21 Jun 2010

European drug companies' lead in making medicines available to developing countries shrinking: Report

European pharmaceutical companies outcompete their U.S. counterparts in making medicines available to people in developing countries, but their lead is shrinking, according to the second Access to Medicine Index, released today.

21 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR).

17 Jun 2010

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Anacor Pharmaceuticals today announced that a Joint Research Committee, composed of both GlaxoSmithKline (GSK) and Anacor employees, has determined that AN3365, a novel systemic antibiotic derived from Anacor's boron chemistry platform, has achieved proof of concept as defined under the collaboration agreement between GSK and Anacor.

15 Jun 2010

Global Programme seeks to eliminate Lymphatic Filariasis by 2020

Representatives from more than 50 countries attended the Sixth Meeting of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF) in Seoul last week, to review the progress of the Global Programme to Eliminate Lymphatic Filariasis (Global Programme), which seeks to eliminate the disease by 2020.

14 Jun 2010

Pfizer to join SGC-led collaboration to generate chemical probes for proteins involved in epigenetic signalling

The Structural Genomics Consortium (SGC) and Pfizer today announced that Pfizer will join the SGC-led public-private collaboration to generate small molecule inhibitors - "chemical probes" - for proteins involved in epigenetic signalling.

11 Jun 2010

Human Genome Sciences submits BLA for BENLYSTA to FDA

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

10 Jun 2010

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Human Genome Sciences, Inc. today announced that GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

7 Jun 2010

BMJ report questions WHO advisors' ties to pharmaceutical industry

"Key scientists behind World Health Organization advice on stockpiling of pandemic flu drugs had financial ties with companies which stood to profit," according to a joint investigation by BMJ in collaboration with the Bureau of Investigative Journalism, BBC News reports (6/4).

5 Jun 2010

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

GlaxoSmithKline today announced that it has received a letter from the U.S. Food and Drug Administration directing revisions to product labeling for its respiratory products Serevent and Advair. The letter concludes discussions between GSK and the agency following FDA advisory committee meetings regarding the safety profile of long-acting beta2-agonists in the treatment of asthma, including salmeterol, the active ingredient in Serevent and one of the active ingredients in Advair.

3 Jun 2010

GlaxoSmithKline News and Research

Rosiglitazone therapy associated with increased risk for heart attack: Study

Research provides hope and encouragement to people living with lupus

Report identifies FDA's weaknesses in monitoring foreign drug trials

BioWa signs two licensing agreements with GSK

Misperceptions about 'light,' 'low,' 'mild' cigarettes

GSK, Medivir sign exclusive agreement for commercialization of Xerclear

European drugmakers lead in making medicines available to developing world, Index says

Opinions: Canada's role in global health; Drug licensing agreements promote drug access; Funding for USAID, state; Haiti

EIN News expands health news-monitoring coverage

GSK acquires exclusive marketing rights for new topical patch from Labtec GmbH

European drug companies' lead in making medicines available to developing countries shrinking: Report

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Anacor's AN3365 novel systemic antibiotic achieves proof of concept

Global Programme seeks to eliminate Lymphatic Filariasis by 2020

Pfizer to join SGC-led collaboration to generate chemical probes for proteins involved in epigenetic signalling

Human Genome Sciences submits BLA for BENLYSTA to FDA

GSK submits BENLYSTA MAA for systemic lupus erythematosus

BMJ report questions WHO advisors' ties to pharmaceutical industry

FDA issues letter directing GSK to revise product labeling for Serevent and Advair

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News